Pain care should do more than move you from pill to referral to procedure.

Start with the problem—not the product

• Arthritis and joint pain — collagen, GLP-1 medicines, and the limits of “regeneration” claims.
• Burning, tingling, and nerve pain — one approved specialist medicine and one early repair candidate.
• Tendon, muscle, and soft-tissue pain — where BPC-157 and TB-500 claims outrun human results.
• FDA-approved peptide pain medicine — yes, one exists, but it is not an online healing peptide.

What the evidence says right now

Established Ziconotide is FDA-approved for selected people with severe chronic pain and is delivered into spinal fluid under specialist care.

Strong, specific result In a 407-person randomized trial, semaglutide improved knee-arthritis pain in people who also had obesity. That does not make it a universal arthritis treatment.

Promising, imperfect Collagen supplements have reduced knee-arthritis symptoms across randomized trials, but products and studies vary and several trials carry meaningful bias.

Not established BPC-157, TB-500, and ARA-290 are not FDA-approved pain treatments. Their human evidence ranges from early and narrow to essentially absent.

See every intervention, evidence grade, regulatory status, and primary source.

Pain is not a single number

There is not always one hidden “root cause.” But good care should still identify the important drivers: joint damage, excess load, nerve injury, inflammation, tendon disease, muscle loss, sleep, mood, or another condition. Changing a pain score without understanding the pattern is not the same as solving the problem.

Peptides may eventually become part of better answers. Some already are medicines. The responsible path is to demand human outcomes, defined material, honest safety data, and a diagnosis that fits—not to trade one blind promise for another.